vs
Side-by-side financial comparison of STONERIDGE INC (SRI) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $103.7M, roughly 2.0× Twist Bioscience Corp). On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -6.0%). STONERIDGE INC produced more free cash flow last quarter ($2.6M vs $-34.8M).
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
SRI vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.2M | $103.7M |
| Net Profit | — | $-30.5M |
| Gross Margin | 16.2% | 52.0% |
| Operating Margin | -14.4% | -31.7% |
| Net Margin | — | -29.4% |
| Revenue YoY | -6.0% | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $-2.76 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.2M | $103.7M | ||
| Q3 25 | $210.3M | — | ||
| Q2 25 | $228.0M | — | ||
| Q1 25 | $217.9M | — | ||
| Q4 24 | $218.2M | — | ||
| Q3 24 | $213.8M | — | ||
| Q2 24 | $237.1M | — | ||
| Q1 24 | $239.2M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $-9.4M | — | ||
| Q2 25 | $-9.4M | — | ||
| Q1 25 | $-7.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.1M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-6.1M | — |
| Q4 25 | 16.2% | 52.0% | ||
| Q3 25 | 20.3% | — | ||
| Q2 25 | 21.5% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 19.5% | — | ||
| Q3 24 | 20.8% | — | ||
| Q2 24 | 22.7% | — | ||
| Q1 24 | 20.2% | — |
| Q4 25 | -14.4% | -31.7% | ||
| Q3 25 | -1.6% | — | ||
| Q2 25 | -1.1% | — | ||
| Q1 25 | -1.5% | — | ||
| Q4 24 | -2.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | -4.5% | — | ||
| Q2 25 | -4.1% | — | ||
| Q1 25 | -3.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -3.3% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | -2.6% | — |
| Q4 25 | $-2.76 | $-0.50 | ||
| Q3 25 | $-0.34 | — | ||
| Q2 25 | $-0.34 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.26 | — | ||
| Q2 24 | $0.10 | — | ||
| Q1 24 | $-0.22 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.3M | $197.9M |
| Total DebtLower is stronger | $180.9M | — |
| Stockholders' EquityBook value | $179.8M | $456.1M |
| Total Assets | $551.2M | $638.1M |
| Debt / EquityLower = less leverage | 1.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $197.9M | ||
| Q3 25 | $54.0M | — | ||
| Q2 25 | $49.8M | — | ||
| Q1 25 | $79.1M | — | ||
| Q4 24 | $71.8M | — | ||
| Q3 24 | $54.1M | — | ||
| Q2 24 | $42.1M | — | ||
| Q1 24 | $48.4M | — |
| Q4 25 | $180.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $201.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $179.8M | $456.1M | ||
| Q3 25 | $251.2M | — | ||
| Q2 25 | $260.5M | — | ||
| Q1 25 | $253.1M | — | ||
| Q4 24 | $245.3M | — | ||
| Q3 24 | $271.4M | — | ||
| Q2 24 | $270.5M | — | ||
| Q1 24 | $277.3M | — |
| Q4 25 | $551.2M | $638.1M | ||
| Q3 25 | $632.1M | — | ||
| Q2 25 | $639.4M | — | ||
| Q1 25 | $657.4M | — | ||
| Q4 24 | $621.6M | — | ||
| Q3 24 | $662.5M | — | ||
| Q2 24 | $666.7M | — | ||
| Q1 24 | $675.4M | — |
| Q4 25 | 1.01× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.8M | $-24.8M |
| Free Cash FlowOCF − Capex | $2.6M | $-34.8M |
| FCF MarginFCF / Revenue | 1.3% | -33.5% |
| Capex IntensityCapex / Revenue | 3.0% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.8M | $-24.8M | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $10.7M | — | ||
| Q1 25 | $10.9M | — | ||
| Q4 24 | $19.2M | — | ||
| Q3 24 | $10.8M | — | ||
| Q2 24 | $8.7M | — | ||
| Q1 24 | $9.1M | — |
| Q4 25 | $2.6M | $-34.8M | ||
| Q3 25 | $-2.7M | — | ||
| Q2 25 | $7.4M | — | ||
| Q1 25 | $4.8M | — | ||
| Q4 24 | $14.0M | — | ||
| Q3 24 | $4.6M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | 1.3% | -33.5% | ||
| Q3 25 | -1.3% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 6.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 3.0% | 9.6% | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.11× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
